News/Events

None at this time.

Registration Closed!

MEACS 2022 Educational Program

We hope to see you next year in Bar Harbor!

ACS Calls for Urgent Action to Address US Firearm Violence Epidemic

In response to recent and continuing firearm violence, the ACS hosted a recent news conference during which leaders of the organization reiterated their commitment to collaborating with lawmakers and communities with the goal of addressing this public health epidemic.

Help Support Victims of the Humanitarian Crisis in Ukraine

Your help is sincerely appreciated.

The ACS is supporting education efforts to ensure citizens of Ukraine know the basics of the STOP THE BLEED® course so that they can implement these lifesaving techniques when needed. Find out More.

Forgotten on the Frontlines

Healthcare’s labor shortage amid the pandemic is leading to stress and burnout among nurses as they seek early retirement, accept temporary travel jobs or change careers

Black Women and Breast Cancer: Experts Discuss Shortcomings in Care

Article in General Surgery News

“Black women have more aggressive breast cancer at a young age than other women, and they’re more likely to die at a young age from these cancers. But they don’t have the same opportunities for screening, genetic testing, treatment and clinical trial participation, experts in oncology reported during a panel session at the 2021 Clinical Congress of the American College of Surgeons.”

Pfizer and BioNTech begin clinical trial for Omicron-specific vaccine

Pfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate, they announced in a news release on Tuesday.

"While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," Pfizer Senior Vice President and Head of Vaccine Research and Development Kathrin Jansen said in the release.